This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Zymergen Inc.
5/12/2022
Good day, and thank you for standing by. Welcome to the Zymergen first quarter 2022 financial results call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you'll need to press star 1 on your telephone. Please be advised that this call is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your host today, Carrie Mendeville from Investor Relations. You may begin.
Thank you. Earlier today, Zymergen released preliminary financial results for the quarter ending March 31st, 2022. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors at zymergen.com. Joining me today from Zymergen are Jay Flatley, Acting Chief Executive Officer, and Ina Sy, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements, in the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled, Forward-Looking Statements and the Press Release Symergen Issue Today. For a more complete list and description, please see the risk factors section of the company's latest 10-K and other filings of the Securities and Exchange Commission, including when filed to form 10-Q for the first quarter of 2022. Except as required by law, Zymogen disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, May 12, 2022. In addition, please note that the first quarter financial results discussed today are preliminary and estimated and are subject to the completion and finalization of Dimerge's financial and accounting closing procedures. With that, I'd like to turn the call over to Jay.
Thanks, Carrie, and good afternoon, everyone. Today, I'll provide a brief update on progress against a few of our key programs, and then Ina will also share a more detailed review of our financials, including preliminary first quarter 2022 results in our forecasted cash runway let me begin by reiterating zymergen's mission to partner with nature to make better products a better way for a better world we committed in august of last year to rapidly transform how zymergen was organized managed and operated that included restructuring and right-sizing our teams instituting a robust product development process trimming refocusing and balancing our product pipeline creating a three-year strategic plan, and extending our cash runway. I've been very pleased with our team's performance to get the new Zymogen operating system fully implemented. This infrastructure provides a foundation for great execution to deliver products in our three businesses of advanced materials, drug discovery, and automation. As a reminder, our strategy is distinctly committed to bringing products to the market, designing and producing molecules, microbes, and materials for diverse end markets. Those markets include four in advanced materials, namely agriculture, water repellency, advanced polymers, and enzymes. Drug discovery, where we leverage our metagenomic database to uncover molecular matter that inhibit targets of interest, focused initially in oncology and on partnerships with biopharmaceutical companies. And we began to offer our proprietary automation technology outside of Zymogen in January of this year. As I mentioned earlier, one of the key transformations we made was to create a nimble, disciplined product development process. We were fully implemented by the end of last year, with all programs operating under this structure. Since year end, we've had three programs advance a phase, and we've promoted two research programs into our product development pipeline, both of which are in one of the four market segments that we've been targeting. Our nitrogen fixation program is delivering engineered microbes to a partner, that replaces the requirement to use nitrogen fertilizer. The production of this fertilizer consumes one to two percent of the world's energy with field runoff that creates algae blooms and dead zones in waterways around the globe. We believe that microbes can ultimately meet all of corn's nitrogen needs and can be expanded to include additional cereal crops such as wheat and sorghum as well as other nutrients. To ensure that microbes will have consistent performance in a variable agricultural environment, we measure strain performance in a suite of assays, each of them representing very specific conditions. This is a process of iterative improvement. Our Gen 1 microbes validated the predictive power of our lab assays. Based on that, we're quite optimistic about the Gen 2 microbes being planted now, and we're already hard at work on Gen 3 for 2023 trials. Our best Gen 3 microbes are early in development But the best variant is already showing over a 50% improvement against the commercial benchmark under defined lab conditions. And this is after only a few months of work. It's an excellent example of how powerful the iterative learning cycle is that can be implemented using our technology platform. We expect this annual development and test cycle to continue over at least the next few years with continuous improvement in performance features. Next, I'd like to update you on our water repellency program. The first market segment we're exploring is coated straws that improve the mouthfeel and key performance characteristics over paper. We recently demonstrated the successful conversion of our coated paper into an end product manufactured on the actual production line of a potential customer. These included the typical straws used in the fast food industry, as well as straws that are used in plastic wrap on juice boxes. In our research group, we're exploring a family of other uses for our water repellency technology, in packaging applications, as well as in new market segments. Finally, I'd like to talk about our progress in automation. We're increasingly excited about the commercial potential of our automation technology. Having built and operated a large-scale system for years internally, we have a unique and informed view of the challenges that need to be solved to fully automate, maintain, scale, and reconfigure such a system. As a reminder, our design is based on building blocks we call RACs, or reconfigurable automation carts. These modules house units of automation and contain third-party equipment such as robot beds, plate readers, PCR machines, and many other devices. These carts are literally plugged together to form a raceway that moves plates from station to station and are controlled by our cloud-native automation control software called ACS, for which we've recently filed a patent. ACS schedules workflows, which can be interleaved, collects scientific and process data on instrument performance, utilization, and monitors progress all remotely. A collection of racks can scale to any size depending upon throughput and application and can be reconfigured in a matter of hours. We've seen very strong interest from potential customers that run the gamut from startups to very large pharmaceutical and chemical companies. Our pipeline of approximately 30 prospects has given us confidence that our products can address real market needs that are not unique to Zymergen. To give you a sense of the value of this pipeline, a typical 10-rack system would cost somewhere between $1 million and $2.5 million, depending upon instrument mix, with approximately $400,000 in annual software and support costs. I would add that this prospect list was generated solely by word of mouth, as we've done no promotion, nor have we hired any sales teams. To conclude, I wanted to take a minute to illustrate the technical productivity of our teams. One measure of that is the quality and quantity of intellectual property patents that we create and ultimately get issued. We have approximately 98 issued or allowed patents and roughly 261 active or pending applications across 110 families. While the depth and breadth of this portfolio is impressive, perhaps more important are our foundational patents, including one we hold titled High-Throughput Genomic Engineering Platform. This IP establishes a broad territorial fence around our platform. To sum up, I'm pleased with the execution of our team since the start of this year and look forward to updating you on our progress. With that, I'll turn it over to Ina to update you on our financials.
You're reading a preview of the ZY Q1 2022 earnings call.
Free account.